Project Grant HT94252510105
Award Date
3/1/25
Completion Date
2/29/28
Dollars Obligated
$1.3M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14203, USA
Similar Awards
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
The Defense Health Agency awarded $780,749 to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research into novel combination immune therapy regimens for metastatic breast cancer. The three-year project grant, beginning February 1, 2023, will fund the development of innovative medical solutions through basic, applied, and advanced biomedical research. Specifically, the awardee will investigate new...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,710,727.00 in funding to Health Research, Inc. (a non-profit organization) to conduct research on targeting the BRSK2 gene in aggressive breast cancer brain metastasis. The award period runs from Sep 30, 2024 to Sep 29, 2027. As a prime grantee, Health Research, Inc. will leverage its expertise in cancer biology, immunotherapy development, and biomarker...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research organization,...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $171,700 to Health Research, Inc. to conduct research on the "Mechanism of Anti-SEMA4D Therapy Reversal of Immunosuppression in the Prostate Tumor Microenvironment." The 2-year research project aims to investigate novel cancer immunotherapy approaches to treat prostate cancer. As a non-profit organization, Health Research, Inc. collaborates extensively...
The U.S. Department of Defense's Defense Health Agency awarded Health Research, Inc. a $1,545,300 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "TARGETING MYCAF-DRIVEN CASTRATION-RESISTANT PROSTATE TUMOR GROWTH." The award, which has a performance period of May 1, 2024 to April 30, 2027, will enable Health Research, Inc.'s Roswell Park Division to perform biomedical research and provide scientific services to advance...
This $1,000,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Health Research, Inc. Inc Roswell Park Division Health Research (DBA Health Research-Roswell Park Cancer Institute Division) to target the natural immunosuppressive capabilities of endogenous beta-adrenergic neural pathways. The goal is to prolong vascularized composite allograft (VCA) graft survival and reduce toxicity risks. The...
Health Research, Inc. Roswell Park Division received a $780,750 project grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on mechanisms of immune suppression and potential therapies. The three-year award, made on April 1, 2023, will support investigation into how the protein neuritin mediates reprogramming of myeloid cell populations and its role in immune suppression. Through this research, the awardee aims...
The Department of the Army Medical Command awarded a $2.5 million Project Grant to Health Research-Roswell Park Cancer Institute Division through the Military Medical Research and Development program (CFDA 12.420). The grant funding will support research efforts to target stress pathways in esophagus cancer in order to boost anti-tumor immunity, promote response to therapy, and prolong patient survival. Through September 2022 to August 2026, Health Research-Roswell Park Cancer Institute Division...
Health Research, Inc. Inc Roswell Park Division Health Research Division (the Division) was awarded a $693,987 project grant from the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420). The grant will fund cancer immunotherapy research from June 1, 2023 through May 31, 2026. Specifically, the Division will investigate strategies to counter solid tumor antigen immune escape using CAR T cell therapies. As a past recipient of Defense Health Agency...